A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy

Maxi Wass, Stefanie Göllner, Birgit Besenbeck, Richard F. Schlenk, Petra Mundmann, Joachim R. Göthert, Richard Noppeney, Christoph Schliemann, Jan‐Henrik Mikesch, Georg Lenz, Martin Dugas, Martin Wermke, Christoph Röllig, Martin Bornhäuser, Hubert Serve, Uwe Platzbecker, Kathrin I. Foerster, Jürgen Burhenne, Walter E. Haefeli, Lutz Müller, Mascha Binder, Caroline Pabst, Carsten Müller‐Tidow, on behalf of the Study Alliance Leukemia (SAL)